目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T63155 | |||
MMP-9-IN-3 是一种 MMP-9 抑制剂 (IC50: 5.56 nM),可与 MMP-9 形成氢键。MMP-9-IN-3 对 AKT 的活性具有抑制作用 (IC50: 2.11 nM)。MMP-9-IN-3 具有细胞毒性,能够诱导细胞凋亡。MMP-9-IN-3 能够用于研究癌症。 | |||
T63994 | |||
MMP-9-IN-4 是 MMP-9 抑制剂,能够与 MMP-9 形成 H-π 相互作用,IC50 值为 7.46 nM。MMP-9-IN-4 还能够抑制 AKT 活性,其 IC50 值为 8.82 nM。MMP-9-IN-4 能够诱导细胞凋亡 (apoptosis),显示出细胞毒性,能够用于研究癌症。 | |||
T81777 | |||
MMP-9-IN-8(Compound 3)是MMP-9抑制剂,10 μM浓度下抑制活性为42.16%,50 μM时达58.28%。该化合物展现抗癌活性,能诱导MCF-7细胞凋亡,IC50为23.42 μM。 | |||
T64083 | |||
MMP-9-IN-5 是一种 MMP-9 抑制剂,其 IC50 值为 4.49 nM,能够与 MMP-9 形成氢键。MMP-9-IN-5 也抑制 AKT 活性,其 IC50 值为 1.34 nM。MMP-9-IN-5 表现出细胞毒性,可诱导细胞凋亡 (apoptosis),能够用于研究癌症。 | |||
T62555 | |||
MMP-2/9-IN-1 (Compound 4a) 是一种有效的 MMP-2 (IC50: 56 nM) 和 MMP-9 (IC50: 38 nM) 双重抑制剂。MMP-2/9-IN-1 对肿瘤生长具有抑制作用,明显诱导癌细胞凋亡 (apoptosis),抑制细胞迁移,并抑制细胞周期进程导致 DNA 片段化。 | |||
T16966 | MMP | ||
S 3304 是一种新型的基质金属蛋白酶抑制剂,能够特异的抑制MMP-2和MMP-9的活性。 | |||
T6885 | MMP | ||
Marimastat (BB2516) 是一种血管生成和转移抑制剂,限制血管的生长和生成。它是一种广谱的,具有口服活性的MMPs 抑制剂,有效抑制 MMP-9 , MMP-1, MMP-2, MMP-14, MMP-7,用于癌症的研究。 | |||
TP1741L | MMP | ||
Histatin 5 acetate 抑制宿主基质金属蛋白酶 MMP-2 和 MMP-9 的活性,IC50 分别为 0.57 和 0.25 μM。 | |||
T12539L | MMP | ||
Prinomastat inhibits MMP-2, MMP-3 and MMP-9 (Kis: 0.05 nM, 0.3 nM and 0.26 nM, respectively). Prinomastat crosses the blood-brain barrier. It also has antitumor activity. Prinomastat is a broad-spectrum, potent, orally active metalloproteinase inhibitor ( | |||
T61271 | MMP | ||
MMP2-IN-3是一种有效的基质金属蛋白酶(MMP-2)抑制剂( IC50 值:31 μM)。MMP2-IN-3 抑制 MMP-9 和 MMP-8 ,其 IC50 分别为 26.6 和 32 μM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01248 | MMP-9 Protein, Human, Recombinant | Human | HEK293 Cells | ||
MMP-9 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 76.3 kDa and the accession number is P14780.
|
|||||
TMPY-01919 | MMP-9 Protein, Mouse, Recombinant | Mouse | HEK293 Cells | ||
MMP-9 Protein, Mouse, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 78.4 kDa and the accession number is P41245-1.
|
|||||
TMPY-00888 | MMP-9 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
MMP-9 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 77.7 kDa and the accession number is P14780.
|
|||||
TMPK-00503 | MMP-9 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 77.44 kDa and the accession number is A0A2K5UU71.
|
|||||
TMPK-00367 | MMP-9 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 79.3 kDa and the accession number is P14780.
|
|||||
TMPJ-00957 | MMP-9 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Matrix metalloproteinases are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix. MMP-9 (gelatinase B) can degrade a broad range of substrates including gelatin, collagen types IV and V, elastin and proteoglycan core protein. It is believed to act synergistically with interstitial collagenase (MMP1) in the degradation of fibrillar collagens as it degrades their denatured gelatin forms. MMP-9 is produced by keratinocytes, monocytes, macrophages and PMN leukocytes. MMP-9 is present in most cases of inflammatory responses. Structurally, MMP-9 may be divided into five distinct domains: a prodomain which is cleaved upon activation, a gelatinbinding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a prolinerich linker region, and a carboxyl terminal hemopexinlike domain.
|
|||||
TMPK-00368 | MMP-9 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Matrix metalloproteinase 9 (MMP9) contributes to this process and deficiencies in the MMP9 lead to impaired healing. Inappropriate expression of MMP9 also contributes to impaired re-epithelialization. Previously we demonstrated that FOXO1 was activated in wound healing but to higher levels in diabetic wounds. To address mechanisms of impaired re-epithelialization we examined MMP9 expression in vivo in full thickness dermal scalp wounds created in experimental K14. MMP-9 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 79.3 kDa and the accession number is P14780.
|
|||||
TMPY-02054 | MMP-9 Protein, Rat, Recombinant (His) | Rat | HEK293 Cells | ||
MMP-9 Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 77.8 kDa and the accession number is A6JXD0.
|
|||||
TMPH-01665 | TIMP3 Protein, Human, Recombinant (His) | Human | E. coli | ||
Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. May form part of a tissue-specific acute response to remodeling stimuli. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15.
|
|||||
TMPJ-01289 | TIMP-4 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Metalloproteinase inhibitor 4 is an enzyme that in humans is encoded by the TIMP4 gene, belongs to the protease inhibitor I35 (TIMP) family. The protein complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9.
|
|||||
TMPJ-00447 | MMP-3 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
MMP3 is a member of the matrix metalloproteinase (MMP) family whose members are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, tissue remodeling, and disease processes including arthritis and metastasis. The MMP-3 enzyme degrades collagen types II, III, IV, IX, and X, proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9, rendering MMP-3 crucial in connective tissue remodeling.[3] The enzyme is thought to be involved in wound repair, progression of atherosclerosis, and tumor initiation.
|
|||||
TMPK-01286 | MMP-8 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Alteration of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) expression has been studied for various cardiac diseases, including dilated cardiomyopathy (DCM), with the significance of surrogate markers of extracellular matrix (ECM) remodeling. MMP-8 was identified only in myocardiocytes, while MMP-9 and TIMP-2 were present in both myocardiocytes and stroma, but with different intensity. The increasing intensity of MMP-8 and TIMP-2 immunoreactions was significantly associated with low HCS.
|
|||||
TMPJ-00865 | VEGF121 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
|
|||||
TMPJ-00082 | NGAL/Lipocalin-2 Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
Lipocalin-2, also known as Neutrophil Gelatinase-Associated Lipocalin (NGAL), is a secretory protein of the lipocalin superfamily. Lipocalin-2 contains a signal peptide that enables it to be secreted and form complexes with matrix metalloproteinase-9 (MMP-9) through disulfide bonds. Similar to other lipocalin family members, Lipocalin-2 is involved in diverse cellular processes, including the transport of small hydrophobic molecules, protection of MMP-9 from proteolytic degradation, and cell signaling. Furthermore, Lipocalin-2 can tightly bind to bacterial siderophore through a cell surface receptor, possibly serving as a potent bacteriostatic agent by sequestering iron, regulating innate immunity and protecting kidney epithelial cells from ischemia–reperfusion injury. This protein is mainly expressed in neutrophils and in lower levels in the kidney, prostate, and epithelia of the respiratory and alimentary tracts.Recent evidence also suggests its role as a biomarker for renal injury and inflammation.
|
|||||
TMPY-03698 | VEGF121b Protein, Human, Recombinant | Human | HEK293 Cells | ||
VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9.
|
|||||
TMPH-00005 | YAP1 Protein, Human, Recombinant (Isoform 9, His) | Human | P. pastoris (Yeast) | ||
YAP1 Protein, Human, Recombinant (Isoform 9, His) is expressed in yeast with C-6xHis tag. The predicted molecular weight is 56.4 kDa; 80 kDa, reducing conditions and the accession number is P46937-9.
|
|||||
TMPJ-00948 | Endostatin Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Endostatin, an endogenous non‑glycosylated inhibitor of endothelial cell proliferation and angiogenesis. It is produced and/or trimmed by metalloproteinases such as MMP‑2 and MMP‑9, and cathepsins S, B and L. The N‑terminal ~27 aa of Endostatin appear to contain the majority of its activity. This region contains zinc binding sites that are thought to be critical for its anti‑endothelial and anti‑tumor effects, as well as multiple cleavage sites that, when used, can modify its activity. Mouse Endostatin shares 96% aa sequence identity with rat and 85‑87% with human, bovine and equine Endostatin. It is predominantly expressed in liver, kidney, lung, skeletal muscle and testis. Endostatin inhibits endothelial cell growth by inducing cell cycle arrest in G1 phase and initiating apoptosis. It is also thought to down‑regulate angiogenesis by blocking VEGF‑induced endothelial cell migration. Endostatin may also be involved with down‑regulation of angiogenesis after establishment of placental circulation in the pregnant uterus.
|
|||||
TMPY-00886 | MMP-1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
MMP1, also known as MMP-1, contains 4 hemopexin-like domains and is a member of the matrix metalloproteinase (MMP) family. Matrix metalloproteases, also called matrixins, are zinc-dependent endopeptidases that are the major proteases involved in ECM degradation. MMPs are capable of degrading a wide range of extracellular molecules and some bioactive molecules. MMP activity is regulated by two major endogenous inhibitors: alpha2-macroglobulin and tissue inhibitors of metalloproteases (TIMPs). MMPs play a central role in cell proliferation, migration, differentiation, angiogenesis, apoptosis, and host defenses. Dysregulation of MMPs has been implicated in many diseases including arthritis, chronic ulcers, encephalomyelitis, and cancer. Tumour metastasis is a multistep process involving the dissemination of tumor cells from the primary tumor to secondary at a distant organ or tissue. One of the first steps in metastasis is the degradation of the basement membrane, a process in which MMPs have been implicated. MMPs are secreted by tumor cells themselves or by surrounding stromal cells stimulated by the nearby tumor. Numerous studies have linked altered MMP expression in different human cancers with poor disease prognosis. MMP-1, -2, -3, -7, -9, -13 and -14 all have elevated expression in primary tumors and/or metastases. MMP-1 cleaves collagens of types I, II, and III at one site in the helical domain. It also cleaves collagens of types VII and X. In case of HIV infection, MMP1 interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity.
|
|||||
TMPY-02404 | ADAM9 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
ADAM9 (A disintegrin and metallopeptidase domain 9, MDC9, meltrin gamma), is a type 1 transmembrane protein that has been associated with cancer development and metastases. ADAM9 is consistently overexpressed in various human cancers, and plays a role in tumorigenesis in mouse models. ADAM9 cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as EGF, FGFR2iiib, Tie-2, Flk-1, EphB4, CD40, VCAM-1, and VE-cadherin, and could represent a potential therapeutic target in tumors where it is highly expressed. ADAM9 belongs to a family of transmembrane, disintegrin-containing metalloproteinases involved in protein ectodomain shedding and cell-cell and cell-matrix interactions. ADAM-9 adhesive domain plays a role in regulating the motility of cells by interaction with beta1 integrins and modulates MMP synthesis.
|
|||||
TMPJ-01060 | CXCL6 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Chemokine (C-X-C-Motif) Ligand 6 (CXCL6) is a small cytokine belonging to the CXC chemokine family. It is a potent neutrophil chemotactic and activating factor and it exhibits extensive similarity to other CXC chemokines such as IL-8 and ENA-78. CXCL6 can promote the release of MMP-9 from granulocytes indicating its potential role as an inflammatory mediator. It functionally uses both of the IL-8/CXCL8 receptors to chemoattract neutrophils but that is structurally most related to epithelial cell-derived neutrophil attractant-78 (ENA-78)/CXCL5. The human CXCL6 gene has been cloned and is physically mapped to the CXC chemokine locus on chromosome 4. Mature human CXCL6 is a 75 amino acid (aa) protein with a predicted molecular weight of approximately 8 kDa. Human CXCL6 shares 60% and 67% aa identity with mouse and bovine CXCL6, respectively.
|
|||||
TMPK-00825 | VEGF121 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9.
|
|||||
TMPK-00826 | VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9.
|
|||||
TMPY-05268 | Neurofascin Protein, Human, Recombinant (hFc), Biotinylated | Human | HEK293 Cells | ||
Neurofascin Protein, Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 130 kDa and the accession number is O94856-9.
|